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INTRODUCTION
More than 1 million individuals in the United
States are living with rheumatoid arthritis (RA) [1] . Strong evidence now suggests that early diagnosis and aggressive treatment alter the natural history of RA [2] . Treatment is usually initiated with a synthetic, non-biologic, diseasemodifying antirheumatic drug (DMARD) to decrease symptoms, limit joint damage, and improve long-term outcomes [3, 4] . As a welltolerated, once-weekly oral agent, methotrexate (MTX) is the cornerstone of many treatment regimens and usually the initial DMARD selected for mild, moderate, or severe disease [3, 5] . Over the last decade, several new and potent DMARDs have been approved by the US Food and Drug Administration for the management of RA [6] . These agents, biologic DMARDs, block the effects of cytokines or of immune effector cells or their cell-to-cell interactions [7] . Use of these agents is generally reserved for patients who have failed or are resistant to non-biologic DMARDs, or who have a high level of disease activity at the time of diagnosis and features of poor prognosis [8] .
As the therapeutic landscape for RA [12] used data from the CORRONA registry to evaluate rheumatologists' prescribing patterns before and after the 2008 publication of the ACR RA treatment recommendations. These investigators found that publication of the guidelines did not significantly change management of patients with active RA [12] .
To support the most relevant and effective educational activities for rheumatologists throughout the US, there must be an understanding not only of the practice gaps related to standards of care, but also the readiness of US rheumatologists to change their practice decisions, and the barriers and challenges they face in managing their patients.
The information gathered through prospective assessment allows for the delivery of more effective and tailored educational activities based on specific audience needs in order to reduce barriers to care. Furthermore, the information gathered in this type of assessment can be used as a baseline to accurately and objectively measure the outcomes and effectiveness of future educational initiatives. This national study was conducted to prospectively evaluate current US rheumatologists' practice patterns with regard to the diagnosis and management of RA, familiarity and agreement with guidelines for classification and treatment of RA, and methods of patient communication. 
METHODS

Compliance with Ethics Guidelines
This study does not contain any new studies with human or animal subjects performed by any of the authors.
RESULTS
Respondent Demographics
Respondent demographics are shown in Table 3 Measures used to assess RA disease severity at diagnosis and during treatment, and consistency of their use When respondents were given a selection of five possible therapeutic changes that they could make in the regimen for a patient whose RA has been well controlled by MTX and a TNFi for 2 years, 53% would not change the regimen, 43% would reduce the dose of MTX, 2% would reduce the dose of TNFi, 1% would discontinue the TNFi, and 1% would discontinue the MTX.
Rheumatologists were evenly split over what to do when a TNFi was ineffective. Forty-eight percent of respondents would try a different TNFi, while 49% would opt for a biologic agent from a different class, 1% would not start another agent, 1% would start a non-biologic DMARD, and 2% selected other. A difference was found between rheumatologists in solo practice versus those in group practice, with 63% of those in solo practice opting for a biologic agent from another class while 41% of those in group practice reported that they would do so.
Biologic Therapy: Knowledge and Attitudes
Prior to starting a biologic therapy, most respondents (87%) would order hepatitis B serologies, and nearly all would order a test for tuberculosis (TB) with either a tuberculin skin test or QuantiFERON (66 and 46%, respectively; Fig. 1 ). Hepatitis C serologies would be obtained by a large majority (79%) of respondents, and a small percentage (14%) would test for HIV.
Most respondents would be very likely to stop biologic therapy for a patient with RA because of serious side effects, lack of efficacy, or infection. In addition, approximately twothirds (62%) said they would be very likely to stop biologic therapy for an infusion reaction and 21% would be 'very likely' to stop for an injection site reaction. Only 9% said they would be very likely to stop a biologic therapy because the patient was in remission; however, 42% said they would be 'somewhat likely' to do so ( Fig. 2a) . When asked about their level of concern regarding potential toxicities of biologic agents, half of respondents were very concerned about bacterial infections, and 43% were very concerned about opportunistic infections, including TB. A quarter or fewer of respondents were very concerned about infusion reactions, lymphoma and other Fig. 1 Tests routinely ordered prior to starting a patient with rheumatoid arthritis (RA) on biologic therapy for the first time. Respondents were able to ' 'select all that apply' ' malignancies (27, 22 and 18%, respectively; Fig. 2b ).
Recurrent infections were considered a very significant barrier to prescribing biologic agents to the large majority (80%) of respondents.
Patient comorbidities and insurance restrictions that limit physicians to prescribing a specific agent or agents in the class were also regarded as very significant barriers (Fig. 2c) .
Patient Communication
Almost all (98%) respondents indicated that they provide the initial education to their patients about RA and RA medications The majority of respondents spend less than 20 min engaged in educational conversations with their patients, regardless of the subject matter ( Fig. 3) .
DISCUSSION
Approaches to the management of RA continue to evolve based on an increased understanding of its pathogenesis and comorbidities and with the development of new agents to address these issues. In the past decade, many highly effective DMARDs with a variety of mechanisms of action have been developed. To address the availability of these new agents, both the ACR and EULAR have recently updated their RA management guideline documents. As knowledge about RA increases, and as novel agents to treat it become available, it is important to assess rheumatologists' practice patterns with respect to managing the disease. DMARDs and about society guidelines for using them. Gathering information on barriers that may prevent the use of these agents can help focus educational strategies for overcoming them. However, few recent studies have been published on this topic. This study adds to the available information and helps to inform future education for rheumatologists.
This includes elucidating rheumatologists' knowledge of and attitudes about new
Less than two-thirds of survey respondents said they were very familiar with the 2012 ACR RA guideline update and less than half were very familiar with the EULAR RA guidelines.
Despite this, most respondents in the current study elected to treat a newly diagnosed RA 
Limitations
This study used a case-vignette survey as a surrogate measure of rheumatologists' skills and knowledge and did not attempt to verify any information with chart audits or direct observation of practice. However, the use of case vignettes (as compared with chart review and standardized patients) has been shown to provide valid and reliable data on clinicians' actual practice patterns [20] . The three clinical scenarios that were used in this study do not cover the full spectrum of RA patient scenarios.
Future studies should investigate other situations, patient types, and comorbidities in order to be more inclusive of the practice patterns used in the US. The study population contained significantly more male respondents and solo practitioners than the population of rheumatologists listed in the AMA 2011 report, which could have affected responses. There may have been a responder bias based on rheumatologists' willingness to respond to online surveys, time availability, or other responder or non-responder characteristics.
Finally, the small honorarium offered to complete the study and limiting the survey to the first 125 responses could have established a selection bias in rheumatologist responses.
CONCLUSION
Although the results of this study indicate that the respondents were not very familiar with current RA guidelines, it did highlight they are providing guideline-congruent care. We found disagreement on how to manage a patient in remission amongst respondents; however, evidence for any particular strategy is lacking.
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